Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Leases (2019 - 2025)

Avalo Therapeutics filings provide 7 years of Leases readings, the most recent being $336000.0 for Q4 2025.

  • On a quarterly basis, Leases fell 54.66% to $336000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $336000.0, a 54.66% decrease, with the full-year FY2025 number at $336000.0, down 54.66% from a year prior.
  • Leases hit $336000.0 in Q4 2025 for Avalo Therapeutics, down from $402000.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $2.0 million in Q4 2021 to a low of $336000.0 in Q4 2025.
  • Median Leases over the past 5 years was $1.2 million (2024), compared with a mean of $1.2 million.
  • Biggest five-year swings in Leases: surged 159.74% in 2022 and later tumbled 64.71% in 2025.
  • Avalo Therapeutics' Leases stood at $2.0 million in 2021, then fell by 12.54% to $1.8 million in 2022, then decreased by 24.06% to $1.3 million in 2023, then plummeted by 44.24% to $741000.0 in 2024, then crashed by 54.66% to $336000.0 in 2025.
  • The last three reported values for Leases were $336000.0 (Q4 2025), $402000.0 (Q3 2025), and $487000.0 (Q2 2025) per Business Quant data.